Aptullahoglu, E. Et Al. 2025. Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia. CANCERS , vol.17, no.2 , 1-17.

Aptullahoglu, E., Howladar, M., Wallis, J. P., Marr, H., Marshall, S., Irving, J., ... Willmore, E.(2025). Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia. CANCERS , vol.17, no.2, 1-17.

Aptullahoglu, ERHAN Et Al. "Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia," CANCERS , vol.17, no.2, 1-17, 2025

Aptullahoglu, ERHAN Et Al. "Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia." CANCERS , vol.17, no.2, pp.1-17, 2025

Aptullahoglu, E. Et Al. (2025) . "Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia." CANCERS , vol.17, no.2, pp.1-17.

@article{article, author={ERHAN APTULLAHOĞLU Et Al. }, title={Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia}, journal={CANCERS}, year=2025, pages={1-17} }